Mo Hongying, Zeng Guangqiao, Ren Xiaolan, Li Hui, Ke Changwen, Tan Yaxia, Cai Chaoda, Lai Kefang, Chen Rongchang, Chan-Yeung Moira, Zhong Nanshan
Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College, China.
Respirology. 2006 Jan;11(1):49-53. doi: 10.1111/j.1440-1843.2006.00783.x.
Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS-coronavirus (SARS-CoV) in SARS patients and evaluated the clinical significance of these antibodies.
Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti-SARS-CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms.
The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1-7, 8-14, 15-21, 22-28, 29-60, 61-90, 91-180 and 181-720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients.
The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS-CoV infection for up to 2 years.
严重急性呼吸综合征（SARS）是一种由新型冠状病毒引起的新发现疾病。本研究对SARS患者体内抗SARS冠状病毒（SARS-CoV）抗体的纵向变化情况进行了研究，并评估了这些抗体的临床意义。
采用酶联免疫吸附测定（ELISA）和间接免疫荧光法两种方法，对98例SARS患者的335份系列血清进行抗SARS-CoV IgG和IgM检测。对18例患者，在症状出现后7至720天研究血清抗体变化情况并进行抗体中和试验。
ELISA检测的IgG/IgM阳性率在症状出现后1至7天、8至14天、15至21天、22至28天、29至60天、61至90天、91至180天和181至720天分别为0/0、45.4/39.4、88.6/71.4、96/88、100/48.6、100/30.9、100/17.1、100/0%。发病后前7天未检测到抗体，但IgG滴度在第15天急剧升高，在第60天达到峰值，并一直保持高水平直到第180天，此后逐渐下降直至第720天。IgM在第15天被检测到并迅速达到峰值，然后逐渐下降直至在第180天无法检测到。在SARS患者的康复血清中检测到中和病毒抗体。
可检测到的IgG抗体和中和病毒抗体持续长达720天，这表明SARS患者可能在长达2年的时间内免受SARS-CoV再次感染。
